Eventually, in due course of disease, PCa becomes resistant to androgen-deprivation therapy (ADT) – castration resistant PCa (CRPC) – disclosing raising serum PSA levels and/or clinical/imagiological tumor progression despite testosterone castrate levels (12). This evidence concerns the gene KLK3 and posterior cortical atrophy.